
    
      This is an open label, multicenter, dose escalation and multidose study of MDX-11-5, a fully
      human monoclonal IgG4 antibody targeting the Programed Death-Ligand 1 (PD-L1).

      The study will consist of 3 periods: Screening (up to 28 days), Treatment (up to 16 six-week
      cycles), and Follow-up (up to 6 months).
    
  